JP2014524469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524469A5 JP2014524469A5 JP2014527196A JP2014527196A JP2014524469A5 JP 2014524469 A5 JP2014524469 A5 JP 2014524469A5 JP 2014527196 A JP2014527196 A JP 2014527196A JP 2014527196 A JP2014527196 A JP 2014527196A JP 2014524469 A5 JP2014524469 A5 JP 2014524469A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- administered
- leukemia
- antimetabolite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 230000000340 anti-metabolite Effects 0.000 claims 7
- 229940100197 antimetabolite Drugs 0.000 claims 7
- 239000002256 antimetabolite Substances 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 claims 5
- 229960000801 nelarabine Drugs 0.000 claims 5
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 4
- 229960004117 capecitabine Drugs 0.000 claims 4
- 229960000684 cytarabine Drugs 0.000 claims 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 201000011649 lymphoblastic lymphoma Diseases 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 238000011319 anticancer therapy Methods 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229960005079 pemetrexed Drugs 0.000 claims 2
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- -1 triazolone compound Chemical class 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 206010069755 K-ras gene mutation Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161525375P | 2011-08-19 | 2011-08-19 | |
| US61/525,375 | 2011-08-19 | ||
| US201161555787P | 2011-11-04 | 2011-11-04 | |
| US61/555,787 | 2011-11-04 | ||
| PCT/US2012/051316 WO2013028505A1 (en) | 2011-08-19 | 2012-08-17 | Combination cancer therapy of hsp90 inhibitor with antimetabolite |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014524469A JP2014524469A (ja) | 2014-09-22 |
| JP2014524469A5 true JP2014524469A5 (OSRAM) | 2015-09-10 |
Family
ID=46759073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527196A Withdrawn JP2014524469A (ja) | 2011-08-19 | 2012-08-17 | 代謝拮抗剤とｈｓｐ９０阻害剤の組み合わせ癌療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20140296176A1 (OSRAM) |
| EP (1) | EP2744494A1 (OSRAM) |
| JP (1) | JP2014524469A (OSRAM) |
| AU (1) | AU2012299177A1 (OSRAM) |
| CA (1) | CA2844809A1 (OSRAM) |
| EA (1) | EA201490472A1 (OSRAM) |
| WO (1) | WO2013028505A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2035396T3 (pl) | 2006-05-25 | 2014-10-31 | Synta Pharmaceuticals Corp | Związki triazolowe modulujące aktywność hsp90 |
| EP2323737A2 (en) | 2008-08-08 | 2011-05-25 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
| US9439899B2 (en) | 2011-11-02 | 2016-09-13 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors |
| US20140286902A1 (en) | 2011-11-02 | 2014-09-25 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
| CA2854188A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| WO2014018862A1 (en) * | 2012-07-27 | 2014-01-30 | Corning Incorporated | Pharmaceutical compositions comprising a heat shock protein inhibitor and a|purine de novo synthesis inhibitor for treating rheumatoid arthritis or cancer |
| DK3179992T3 (da) | 2014-08-11 | 2022-07-11 | Acerta Pharma Bv | Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor |
| WO2016024232A1 (en) | 2014-08-11 | 2016-02-18 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor |
| DK3179991T3 (da) | 2014-08-11 | 2021-12-06 | Acerta Pharma Bv | Terapeutiske kombinationer af en btk-inhibitor og en bcl-2-inhibitor |
| JP6869899B2 (ja) | 2015-02-13 | 2021-05-12 | サン・ファーマシューティカル・インダストリーズ・リミテッド | 静脈内注入剤形 |
| WO2018236796A1 (en) * | 2017-06-20 | 2018-12-27 | Tarveda Therapeutics, Inc. | Combination therapies comprising targeted therapeutics |
| AU2018289349A1 (en) | 2017-06-20 | 2020-01-02 | Madrigal Pharmaceuticals, Inc. | Combination therapies comprising targeted therapeutics |
| KR20200016875A (ko) | 2017-06-20 | 2020-02-17 | 마드리갈 파마슈티칼스 인코포레이티드 | 표적화 치료제 |
| CN115957328A (zh) * | 2022-07-13 | 2023-04-14 | 杭州百可生物科技有限公司 | 一种用于治疗白血病的药物组合物以及白血病的治疗方法 |
| CN121041304A (zh) * | 2025-11-06 | 2025-12-02 | 哈尔滨医科大学 | Cct018159与奈拉滨联合用药在制备急性白血病药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US20050020534A1 (en) * | 2003-05-30 | 2005-01-27 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites |
| PT1817295E (pt) * | 2004-11-18 | 2013-02-18 | Synta Pharmaceuticals Corp | Compostos de triazol que modulam a actividade da hsp90 |
| WO2012068487A1 (en) * | 2010-11-18 | 2012-05-24 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status |
-
2012
- 2012-08-17 CA CA2844809A patent/CA2844809A1/en not_active Abandoned
- 2012-08-17 WO PCT/US2012/051316 patent/WO2013028505A1/en not_active Ceased
- 2012-08-17 JP JP2014527196A patent/JP2014524469A/ja not_active Withdrawn
- 2012-08-17 EA EA201490472A patent/EA201490472A1/ru unknown
- 2012-08-17 AU AU2012299177A patent/AU2012299177A1/en not_active Abandoned
- 2012-08-17 US US14/239,676 patent/US20140296176A1/en not_active Abandoned
- 2012-08-17 EP EP12753315.6A patent/EP2744494A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524469A5 (OSRAM) | ||
| HRP20160361T1 (hr) | Terapija u kombinaciji s antitumorskim alkaloidom | |
| JP2012521435A5 (OSRAM) | ||
| JP2010533206A5 (OSRAM) | ||
| JP6002835B2 (ja) | 低用量イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| JP2014510729A5 (OSRAM) | ||
| JP2014512356A5 (OSRAM) | ||
| JP2014532704A5 (OSRAM) | ||
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2017537126A5 (OSRAM) | ||
| EA201490472A1 (ru) | Комбинированная терапия рака hsp90-ингибитором и антиметаболитом | |
| JP2021510725A5 (OSRAM) | ||
| ES2625492T3 (es) | Combinación terapéutica que comprende un inhibidor de Cdc7 y un agente antineoplásico | |
| JP2005008534A (ja) | 抗癌剤及び癌の治療方法 | |
| JP2014144962A5 (OSRAM) | ||
| WO2012156380A1 (en) | Method for treatment of advanced solid tumors | |
| JP2020500922A5 (OSRAM) | ||
| JP2007511499A (ja) | コンビネーション | |
| WO2007108272A1 (ja) | 癌治療用キットおよび癌治療用医薬組成物 | |
| CN1615136A (zh) | 包含埃坡霉素和抗代谢物的组合 | |
| CN1917885A (zh) | 抗癌疗法 | |
| JP2020520385A5 (OSRAM) | ||
| JP5976923B2 (ja) | イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| JP2007525507A5 (OSRAM) | ||
| CN1553803A (zh) | 4-吡啶基甲基酞嗪在治疗癌症中的应用 |